Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder.

Oncology reports - 1 Jul 2008

Horikawa Yohei, Nadaoka Junichi, Saito Mitsuru, Kumazawa Teruaki, Inoue Takamitu, Yuasa Takeshi, Tsuchiya Norihiko, Nishiyama Hiroyuki, Ogawa Osamu, Habuchi Tomonori

Abstract excerpt

Recent studies have shown that functional polymorphisms at the MDM2 SNP309 T/G and p53 Arg72Pro may be associated with cancer susceptibility. However, the role of these polymorphisms on the risk of transitional cell carcinoma of the bladder (TCCB) and clinical outcome remains unknown. SNP309 and p53 Arg72Pro polymorphisms were genotyped in 227 patients and 266 control subjects. The association between each...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Transitional Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Staging

Share to Polymorphism, Genetic

Share to Polymorphism, Single Nucleotide

Share to Proto-Oncogene Proteins c-mdm2

Share to Tumor Suppressor Protein p53

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 18575717

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder.PMID 18575717Read ↗

MDM2 T309G polymorphism is associated with bladder cancer.Semantic proximity Read ↗

The MDM2 SNP309T>G polymorphism increases bladder cancer risk among Caucasians: a meta-analysis.Semantic proximity Read ↗

Mdm2 SNP309 G-variant is associated with invasive growth of human urinary bladder cancer.Semantic proximity Read ↗

Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy.Semantic proximity Read ↗

MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis.Semantic proximity Read ↗

A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer.Semantic proximity Read ↗

MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies.Semantic proximity Read ↗

MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.Semantic proximity Read ↗

MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.Semantic proximity Read ↗

p53 codon 72 polymorphism as a progression index for bladder cancer.Semantic proximity Read ↗

MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.Semantic proximity Read ↗

Prognostic implications of p53 gene mutations in bladder tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.